Spots Global Cancer Trial Database for Search for a Link Between Response to Treatment and Circulating Leucocytes in High Grade Glioma Patients

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Search for a Link Between Response to Treatment and Circulating Leucocytes in High Grade Glioma Patients

Official Title: Analysis of Different Circulating Immune Cells in Patients With Recurrent Glioblastoma or Mixed Anaplasic Glioma Treated With Bevacizumab and Search for a Link With Response to Treatment

Study ID: NCT01836536

Conditions

Glioblastoma

Glioma

Interventions

Bevacizumab standard of care

Study Description

Brief Summary: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), is an antiangiogenic treatment currently proposed to recurrent high grade glioma patients. Unfortunately some patients fail to respond to this treatment and finding biological factors allowing the discrimination between potential responders and non responders would be very helpful. As the immune system plays a key role in angiogenesis induction and maintenance in cancer, it could serve as a surrogate marker of angiogenesis in cancer patients. The purpose of this study is to determine the influence of bevacizumab treatment on circulating immune cells in high grade glioma patients and to search for a link between the variation of these cells and the response to treatment.

Detailed Description: The following leucocyte subsets will be analyzed in whole blood before treatment and before cycles 3, 5 and 7: * Classical, intermediate, nonclassical and Tie2 expressing monocytes. * Regulatory T cells (Treg). * Myeloid Derived Suppressor cells (MDSCs) The variation of the absolute numbers (or relative percentages) of the cells in the blood of patients will be correlated to the response to treatment assessed according to the RANO criteria.